CTLTのチャート
CTLTの企業情報
| symbol | CTLT |
|---|---|
| 会社名 | Catalent Inc （CTLT キャタレント） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 キャタレント(Catalent Inc)は薬品、生物製剤及び顧客・動物健康製品向けの配達技術と開発ソリューションの提供を行う。同社は3つの事業区分により構成される。軟質ゲル技術事業は処方箋・顧客健康ソフト・カプセルまたは軟質ゲルの生産・開発・製造に従事する。薬物配達ソリューション事業は処方箋・顧客・動物健康製品の生産・開発・製造、ブロー・フィル・シール・ユニット・ドーズ製造、生物的細胞株開発、分析と生物分析開発及びテスト・サービスの提供に従事する。臨床供給サービス事業は診療試験薬物と生物製剤の製造・包装・ラベル付け・ストレージ・販売・在庫管理、FastChain臨床供給サービスの提供、臨床電子ソリューションと情報及びグローバルな対照薬供給サービスの提供に従事する。 キャタレントは米国の製薬会社。処方箋薬、市販薬、生物製剤向けに経口剤、注射剤、吸引剤などの発見、開発、受託製造を行う。また、治験薬の製造・供給、各種包装・容器の製造、在庫管理サ―ビスを提供。顧客は米国、欧州、アジア、南米の大手製薬会社や新興製薬企業。 Catalent, Inc., an S&P 500® Company, is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 14,000 people, including over 2,400 scientists and technicians, at more than 40 facilities across four continents, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. |
| 本社所在地 | 732 537-6200 |
| 代表者氏名 | John R. Chiminski |
| 代表者役職名 | Chairman of the Board Chief Executive Officer |
| 電話番号 | +1 732-537-6200 |
| 設立年月日 | 39173 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 10700人 |
| url | www.catalent.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 506.80000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 5911.23100 |
| 売上高 | 売上高（百万ドル） 2488.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 7903.23100 |
| 当期純利益 | 当期純利益（百万ドル） 132.90000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 31 December 2018 Catalent Inc revenues increased 2% to $1.17B. Net income before extraordinary items increased 24% to $34.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Debt refinancing costs decrease of 64% to $4.2M (expense) Foreign currency (gains) and losses decrease of 65% to $2.4M (expense). |
CTLTのテクニカル分析
CTLTのニュース
What will the future hold for Catalent Inc. (NYSE:CTLT) stock? 2022/08/31 17:16:00 US Post News
Currently, Catalent Inc.’s (CTLT) stock is trading at $87.96, marking a fall of -1.48% from last night’s close. At this price, the stock is -38.33% below its 52-week high of $142.64 and 1.88% above its 52-week low of $86.34. Based on the past 30-day period, the stock price is -23.00% below the high and +0.31% […]
Catalent Faces Several Price Target Cuts By Analysts After Q4 Results 2022/08/30 12:36:29 Benzinga
Catalent, Inc. (NYSE: CTLT ) reported mixed results for its fourth quarter on Monday. For FY23, Catalent said it expects $4.975-$5.225 billion in revenue compared to the consensus of $5.26 billion. Catalent shares fell 0.9% to $91.50 in pre-market trading after dropping 7.4% on Monday. Several analysts made changes to their price targets on Catalent … Full story available on Benzinga.com
Catalent PT Lowered to $110 at Jefferies 2022/08/30 12:10:02 Investing.com
https://www.investing.com/news/pro/catalent-pt-lowered-to-110-at-jefferies-432SI-2882504
Catalent PT Lowered to $123 at Baird 2022/08/30 10:29:02 Investing.com
https://www.investing.com/news/pro/catalent-pt-lowered-to-123-at-baird-432SI-2882382
Catalent PT Lowered to $125 at RBC Capital 2022/08/30 10:21:06 Investing.com
https://www.investing.com/news/pro/catalent-pt-lowered-to-125-at-rbc-capital-432SI-2882367
Novo Holdings A/S Buys 4, Sells 1 in 1st Quarter 2022/05/18 19:00:03 GuruFocus
Related Stocks: CMPI , NKTX , EVO , ASML , CTLT ,
The Biopharmaceuticals Contract Manufacturing Market to Witness Tremendous Growth with a CAGR of 7.38% During the Study Period (2019-27) | DelveInsight 2022/05/12 17:00:00 Benzinga
New York, USA, May 12, 2022 (GLOBE NEWSWIRE) -- The Biopharmaceuticals Contract Manufacturing Market to Witness Tremendous Growth with a CAGR of 7.38% During the Study Period (2019-27) | DelveInsight As per DelveInsight Analysis in the Biopharmaceuticals Contract Manufacturing market, the demand for contract manufacturing is gaining momentum at present owing to the increase in the investments by the pharmaceutical giants for the research and development of various biologics and biosimilars. Moreover, the advantage of the reduction in overall investment for developing drugs with contract manufacturing is anticipated to raise the adoption of contract manufacturing by biopharma giants in the forthcoming years. According to the latest report published by DelveInsight " Biopharmaceuticals Contract Manufacturing Market Insight " the global Biopharmaceuticals Contract Manufacturing market is projected to witness significant growth owing to the rise in the demand for contract manufacturing by the major biopharmaceutical companies, rising focus on contract manufacturing companies in expanding their capabilities to manufacture biological drugs, presence of robust biologic pipeline among various companies across the globe.
TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update 2022/05/11 20:01:00 GlobeNewswire
Announced Collaboration with Catalent to Further Expand Thin Film Freezing Applications with a Focus on Biologic Drug Development
41 Stocks Moving In Tuesday''s Mid-Day Session 2022/05/03 16:14:47 Benzinga
Gainers SoundHound AI, Inc. (NASDAQ: SOUN ) shares jumped 47.4% to $16.13. The company recently completed a SPAC merger deal last week and began trading on Thursday. Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA ) gained 41% to $3.7680 after the company and its partner MicroSafe Group DMCC received EPA approval for Nanocyn as a hospital-grade disinfectant. Ostin Technology Group Co., Ltd. (NASDAQ: OST ) jumped 30.4% to $3.94. Enovix Corporation (NASDAQ: ENVX ) shares gained 29% to $11.52. Enovix announced initial smartwatch battery order from leading global consumer electronics company. Atkore Inc. (NASDAQ: ATKR ) surged 18.1% to $113.81 after the company reported better-than-expected Q2 EPS and sales results. The company also issued Q2 EPS guidance above analyst estimates. TETRA Technologies, Inc. (NYSE: TTI ) gained 17.6% to $4.35. Tetra Technologies recently posted Q1 adjusted EPS of $0.06. Belite Bio, Inc (NASDAQ: BLTE ) jumped 17.3% to $10.41. The FDA has granted Fast Track Designation to Belite Bio’s LBS-008 for Stargardt disease (STGD1).
Earnings Scheduled For May 3, 2022 2022/05/03 08:52:35 Benzinga
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ: KNSA ) is projected to report earnings for its first quarter. • Great Lakes Dredge & Dock (NASDAQ: GLDD ) is likely to report quarterly earnings at $0.16 per share on revenue of $170.53 million. • Enel Chile (NYSE: ENIC ) is expected to report quarterly earnings at $82.88 per share on revenue of $994.35 million. • Paramount Global (NASDAQ: PARAA ) is likely to report quarterly earnings at $0.52 per share on revenue of $7.38 billion. • Triton International (NYSE: TRTN ) is likely to report quarterly earnings at $2.63 per share on revenue of $419.07 million. • Colliers Intl Gr (NASDAQ: CIGI ) is likely to report quarterly earnings at $1.59 per share on revenue of $1.14 billion. • Comstock Mining (AMEX: LODE ) is projected to report quarterly loss at $0.03 per share on revenue of $380.00 thousand. • GEO Group (NYSE: GEO ) is expected to report quarterly earnings at $0.22 per share on revenue of $551.47 million. • Kopin (NASDAQ: KOPN ) is expected to report quarterly loss at $0.
Novo Holdings A/S Buys 4, Sells 1 in 1st Quarter 2022/05/18 19:00:03 GuruFocus
Related Stocks: CMPI , NKTX , EVO , ASML , CTLT ,
The Biopharmaceuticals Contract Manufacturing Market to Witness Tremendous Growth with a CAGR of 7.38% During the Study Period (2019-27) | DelveInsight 2022/05/12 17:00:00 Benzinga
New York, USA, May 12, 2022 (GLOBE NEWSWIRE) -- The Biopharmaceuticals Contract Manufacturing Market to Witness Tremendous Growth with a CAGR of 7.38% During the Study Period (2019-27) | DelveInsight As per DelveInsight Analysis in the Biopharmaceuticals Contract Manufacturing market, the demand for contract manufacturing is gaining momentum at present owing to the increase in the investments by the pharmaceutical giants for the research and development of various biologics and biosimilars. Moreover, the advantage of the reduction in overall investment for developing drugs with contract manufacturing is anticipated to raise the adoption of contract manufacturing by biopharma giants in the forthcoming years. According to the latest report published by DelveInsight " Biopharmaceuticals Contract Manufacturing Market Insight " the global Biopharmaceuticals Contract Manufacturing market is projected to witness significant growth owing to the rise in the demand for contract manufacturing by the major biopharmaceutical companies, rising focus on contract manufacturing companies in expanding their capabilities to manufacture biological drugs, presence of robust biologic pipeline among various companies across the globe.
TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update 2022/05/11 20:01:00 GlobeNewswire
Announced Collaboration with Catalent to Further Expand Thin Film Freezing Applications with a Focus on Biologic Drug Development
41 Stocks Moving In Tuesday''s Mid-Day Session 2022/05/03 16:14:47 Benzinga
Gainers SoundHound AI, Inc. (NASDAQ: SOUN ) shares jumped 47.4% to $16.13. The company recently completed a SPAC merger deal last week and began trading on Thursday. Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA ) gained 41% to $3.7680 after the company and its partner MicroSafe Group DMCC received EPA approval for Nanocyn as a hospital-grade disinfectant. Ostin Technology Group Co., Ltd. (NASDAQ: OST ) jumped 30.4% to $3.94. Enovix Corporation (NASDAQ: ENVX ) shares gained 29% to $11.52. Enovix announced initial smartwatch battery order from leading global consumer electronics company. Atkore Inc. (NASDAQ: ATKR ) surged 18.1% to $113.81 after the company reported better-than-expected Q2 EPS and sales results. The company also issued Q2 EPS guidance above analyst estimates. TETRA Technologies, Inc. (NYSE: TTI ) gained 17.6% to $4.35. Tetra Technologies recently posted Q1 adjusted EPS of $0.06. Belite Bio, Inc (NASDAQ: BLTE ) jumped 17.3% to $10.41. The FDA has granted Fast Track Designation to Belite Bio’s LBS-008 for Stargardt disease (STGD1).
Earnings Scheduled For May 3, 2022 2022/05/03 08:52:35 Benzinga
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ: KNSA ) is projected to report earnings for its first quarter. • Great Lakes Dredge & Dock (NASDAQ: GLDD ) is likely to report quarterly earnings at $0.16 per share on revenue of $170.53 million. • Enel Chile (NYSE: ENIC ) is expected to report quarterly earnings at $82.88 per share on revenue of $994.35 million. • Paramount Global (NASDAQ: PARAA ) is likely to report quarterly earnings at $0.52 per share on revenue of $7.38 billion. • Triton International (NYSE: TRTN ) is likely to report quarterly earnings at $2.63 per share on revenue of $419.07 million. • Colliers Intl Gr (NASDAQ: CIGI ) is likely to report quarterly earnings at $1.59 per share on revenue of $1.14 billion. • Comstock Mining (AMEX: LODE ) is projected to report quarterly loss at $0.03 per share on revenue of $380.00 thousand. • GEO Group (NYSE: GEO ) is expected to report quarterly earnings at $0.22 per share on revenue of $551.47 million. • Kopin (NASDAQ: KOPN ) is expected to report quarterly loss at $0.